Literature DB >> 33891890

Targeting cell-cycle machinery in cancer.

Jan M Suski1, Marcin Braun2, Vladislav Strmiska1, Piotr Sicinski3.   

Abstract

Abnormal activity of the core cell-cycle machinery is seen in essentially all tumor types and represents a driving force of tumorigenesis. Recent studies revealed that cell-cycle proteins regulate a wide range of cellular functions, in addition to promoting cell division. With the clinical success of CDK4/6 inhibitors, it is becoming increasingly clear that targeting individual cell-cycle components may represent an effective anti-cancer strategy. Here, we discuss the potential of inhibiting different cell-cycle proteins for cancer therapy.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33891890      PMCID: PMC8206013          DOI: 10.1016/j.ccell.2021.03.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   38.585


  167 in total

Review 1.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry.

Authors:  Yutaka Matsumoto; James L Maller
Journal:  Science       Date:  2004-10-29       Impact factor: 47.728

Review 3.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

4.  Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

Authors:  Monica M Mita; Anil A Joy; Alain Mita; Kamalesh Sankhala; Ying-Ming Jou; Da Zhang; Paul Statkevich; Yali Zhu; Siu-Long Yao; Karen Small; Rajat Bannerji; Charles L Shapiro
Journal:  Clin Breast Cancer       Date:  2013-10-26       Impact factor: 3.225

5.  Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E.

Authors:  D M Bortner; M P Rosenberg
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

6.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Authors:  Marta Puyol; Alberto Martín; Pierre Dubus; Francisca Mulero; Pilar Pizcueta; Gulfaraz Khan; Carmen Guerra; David Santamaría; Mariano Barbacid
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

7.  Expression of cell cycle-regulated proteins in prostate cancer.

Authors:  R D Mashal; S Lester; C Corless; J P Richie; R Chandra; K J Propert; A Dutta
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

8.  Development of CDK2 and CDK5 Dual Degrader TMX-2172.

Authors:  Mingxing Teng; Jie Jiang; Zhixiang He; Nicholas P Kwiatkowski; Katherine A Donovan; Caitlin E Mills; Chiara Victor; John M Hatcher; Eric S Fischer; Peter K Sorger; Tinghu Zhang; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2020-06-03       Impact factor: 15.336

9.  Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Authors:  Xin Jin; Donglin Ding; Yuqian Yan; Hui Li; Bo Wang; Linlin Ma; Zhenqing Ye; Tao Ma; Qiang Wu; Daniel N Rodrigues; Manish Kohli; Rafael Jimenez; Liguo Wang; David W Goodrich; Johann de Bono; Haidong Dong; Heshui Wu; Runzhi Zhu; Haojie Huang
Journal:  Mol Cell       Date:  2018-12-06       Impact factor: 17.970

10.  Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.

Authors:  Jian Kang; C Marcelo Sergio; Robert L Sutherland; Elizabeth A Musgrove
Journal:  BMC Cancer       Date:  2014-01-20       Impact factor: 4.430

View more
  45 in total

1.  Design, Synthesis, and Biological Evaluation of Apcin-Based CDC20 Inhibitors.

Authors:  Rajib Bhuniya; Xinrui Yuan; Longchuan Bai; Kathryn L Howie; Rui Wang; Wei Li; Frank Park; Chao-Yie Yang
Journal:  ACS Med Chem Lett       Date:  2022-01-18       Impact factor: 4.345

2.  CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR.

Authors:  Wen-Jun Qin; Yi-Ge Su; Xiao-Long Ding; Ren Zhao; Zhi-Jun Zhao; Yan-Yang Wang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

3.  The phosphatase CTDSPL2 is phosphorylated in mitosis and a target for restraining tumor growth and motility in pancreatic cancer.

Authors:  Yi Xiao; Yuanhong Chen; Aimin Peng; Jixin Dong
Journal:  Cancer Lett       Date:  2021-11-20       Impact factor: 8.679

4.  c-myc-mediated upregulation of NAT10 facilitates tumor development via cell cycle regulation in non-small cell lung cancer.

Authors:  Zimu Wang; Yicong Huang; Wanjun Lu; Jiaxin Liu; Xinying Li; Suhua Zhu; Hongbing Liu; Yong Song
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

Review 5.  Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract.

Authors:  Fuchun Zeng; Yubin Zhou; Theerawat Khowtanapanich; Charupong Saengboonmee
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

6.  Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout.

Authors:  Nobuyuki Ishikura; Masamichi Sugimoto; Keigo Yorozu; Mitsue Kurasawa; Daiko Wakita; Osamu Kondoh
Journal:  Cancer Diagn Progn       Date:  2022-09-03

Review 7.  Cell Cycle-Related Clinical Applications.

Authors:  Md Gulam Musawwir Khan; Yi Wang
Journal:  Methods Mol Biol       Date:  2022

Review 8.  Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy.

Authors:  Agnieszka K Witkiewicz; Vishnu Kumarasamy; Ioannis Sanidas; Erik S Knudsen
Journal:  Trends Cancer       Date:  2022-05-20

Review 9.  Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star.

Authors:  Qun Chen; Jiajia Li; Peng Shen; Hao Yuan; Jie Yin; Wanli Ge; Wujun Wang; Guangbin Chen; Taoyue Yang; Bin Xiao; Yi Miao; Zipeng Lu; Pengfei Wu; Kuirong Jiang
Journal:  Cell Biosci       Date:  2022-06-21       Impact factor: 9.584

10.  Immune dysfunction and reprogramming in RCC.

Authors:  Rebecca Tregunna
Journal:  Nat Rev Urol       Date:  2021-06       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.